Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Scientists at Harvard University in the US are set to collaborate with their Chinese colleagues to develop therapies and diagnostics for the novel coronavirus.

Harvard Medical School will act as the hub for scientists, investigators and clinical researchers from the medical school, its affiliated hospitals and institutes, other regional institutions and biotech companies.

The five-year alliance will see Harvard University and China’s Guangzhou Institute for Respiratory Health share $115m research funding from China Evergrande Group.

Harvard Medical School dean George Daley said: “With the extraordinary scale and depth of relevant clinical and scientific capabilities in our community, Harvard Medical School is uniquely positioned to convene experts in virology, infectious disease, structural biology, pathology, vaccine development, epidemiology and public health to confront this rapidly evolving crisis.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The collaboration aims to gain better insights into the coronavirus’ basic biology and behaviour while working on disease detection and therapeutic design.

As part of the project, the team will focus on developing rapid diagnostic tests, identifying disease biomarkers, as well as creating vaccines, antiviral drugs and treatments.


See all Coronavirus vaccines and drugs in the pipeline

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact